HomeMEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES

Accuray Unveils VOLO™ Ultra, the Latest Innovation for the Radixact® System, at ASTRO 2021

Showcases Multiple Forward-Looking Radiotherapy Solutions Designed to Enhance the Treatment Experience for Medical Care Teams and Their Patients

Accuray Incorporated (NASDAQ: ARAY) announced today the company is showcasing its new VOLO™ Ultra for the Radixact® System, at ASTRO 2021. VOLO Ultra, a new way of planning with the Accuray Precision® Treatment Planning System, enables users to plan with ease, optimize with quality, and deliver treatments with efficiency.

The American Society for Radiation Oncology’s (ASTRO) 63rd annual meeting will take place October 24-27, 2021, in Chicago. Accuray will be in attendance at booth #403, sharing information on how its novel CyberKnife® and Radixact platforms and advanced software solutions can help expand the curative potential of radiation therapy.

“Accuray is thrilled to attend ASTRO 2021 and have the opportunity to engage with our valued customers. We are focused on positioning them for success in an ever evolving healthcare environment,” said Suzanne Winter, president of Accuray. “Our artificial intelligence (AI)-driven Synchrony® 4D dynamic delivery technology on the CyberKnife and Radixact Systems, ClearRT™ imaging, and VOLO Ultra are making it easier than ever to provide precise and accurate radiation treatments – but we aren’t stopping here. We continue to pursue the development of game-changing innovations that have the potential to bring a paradigm shift in radiation delivery and patient outcomes.”

Accuray ASTRO 2021 Highlights: Unique Advances in Software and Imaging Solutions

  • VOLO Ultra*: VOLO Ultra is the latest evolution of our planning solution, the Accuray Precision Treatment Planning System. It helps accelerate Radixact and TomoTherapy® treatments so clinicians can treat more patients each day. It includes a state-of-the-art optimizer with a modern and fast gradient-based algorithm, designed to provide optimal plan quality for every treatment.
  • ClearRT helical fan-beam kVCT imaging**: ClearRT is a one-of-a-kind imaging solution integrated with the Radixact System – a true workhorse system – to produce exceptional diagnostic-like quality CT images, quickly and cost-effectively. ClearRT offers the widest and longest field of view enabling clinicians to see more, know more and do more, and providing a new level of precision and accuracy in the treatment of almost any indication that would benefit from radiotherapy, from the simplest to the most complex.
  • RayStation*** for the CyberKnife**** robotic radiosurgery platform: RayStation treatment planning support for the robotic CyberKnife M6™ and S7™ Systems will help enable clinicians to create treatment plans for these advanced systems and other conventional radiotherapy devices using the same software solution. RayStation will make it easier to seamlessly integrate the CyberKnife System within a radiation oncology department, increasing access to the only device capable of delivering sub-millimetric stereotactic treatments anywhere in the body with speed, efficiency and accuracy – all without the need for human intervention.

Symposium: Go ITV-free and Gating-free with Accuray

  • October 26th, 2021, at 12:15 pm CT in Theater 1, Innovation Hub
  • Hear how Synchrony® enables ITV-free and gating-free approaches to stereotactic body radiation therapy (SBRT) treatments. Three practitioners will share their real-world clinical experiences using Synchrony® with the Radixact® and CyberKnife® Systems.

Click here for more information or to register for the symposia.

Accuray Exchange in Radiation Oncology (AERO™) Sessions: Daily Throughout the Meeting
The 15-minute talks on best practices will be offered in the AERO bar within the Accuray booth. All presentations will be available on AccurayExchange.com. Topics include:

  • Rationale and overview of CyberKnife prostate SBRT
  • Efficiency gains with CyberKnife VOLO™ optimizer: A user’s perspective
  • VOLO™ Ultra, a new way of planning with Accuray Precision® Treatment Planning System, architected to accelerate
  • Implementing ClearRT™ for the Radixact System
  • CyberKnife Synchrony approach for pancreas treatments
  • The impact of the Radixact with Synchrony on patient treatments
  • Introducing CyberKnife planning on RayStation®
  • Brainlab Elements: improved target definition through automation

*VOLO™ Ultra Option for Accuray Precision® Treatment Planning System is 510(k) cleared. It is not CE marked and availability is subject to regulatory clearance or approval in some markets.
**ClearRT™ Helical kVCT Imaging for the Radixact® Treatment Delivery System is not available for sale in all markets. ClearRT may be subject to international regulatory approval or licensing processes such that the availability of these products may vary according to geographical location.
***RayStation: Subject to regulatory clearance in some markets.
****Accuray CyberKnife® System: 510(k) cleared. Subject to regulatory clearance in some markets.

SourceAccuray Incorporated
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society 2023 Annual Meeting

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."

Research Team at UNC Validates PixCell Medical’s HemoScreen as Game-Changer for Clozapine Monitoring in Psychiatry

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).

Inspira Technologies Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients

Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

Medical Device News Magazine

Editorial Contact: mdnewsmagazine@infomeddnews.com

Medical Device News Magazine can help promote your medical devices, technologies, products or services. Advertising Contact: advmdn@infomeddnews.com

Telephone

© Copyright 2022 Medical Device News Magazine, is a division of PTM Healthcare Marketing, Inc

By using this website you agree to accept Medical Device News Magazine Privacy Policy